These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18281730)

  • 61. Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics.
    Schreiner A; Lahaye M; Peuskens J; Naber D; Dilbaz N; Millet B; Franco MA; Rancans E; Turczynski J; Smeraldi E; Lara E; Neznanov NG
    Expert Opin Pharmacother; 2014 Apr; 15(5):593-603. PubMed ID: 24491033
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.
    Berwaerts J; Xu H; Nuamah I; Lim P; Hough D
    J Affect Disord; 2012 Jan; 136(1-2):e51-e60. PubMed ID: 20624657
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations.
    Russu A; Kern Sliwa J; Ravenstijn P; Singh A; Mathews M; Kim E; Gopal S
    Int J Clin Pract; 2018 Jun; 72(6):e13089. PubMed ID: 29707876
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Paliperidone extended-release tablets: a new atypical antipsychotic.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 May; 45(5):15-8. PubMed ID: 17526326
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections.
    Helland A; Syrstad VE; Spigset O
    J Clin Psychopharmacol; 2015 Feb; 35(1):95-6. PubMed ID: 25478938
    [No Abstract]   [Full Text] [Related]  

  • 69. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
    Kim EY; Chang SM; Shim JC; Joo EJ; Kim JJ; Kim YS; Ahn YM
    Curr Med Res Opin; 2013 Oct; 29(10):1231-40. PubMed ID: 23777311
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.
    Singh D; Williams O
    Aust N Z J Psychiatry; 2012 Feb; 46(2):176-7. PubMed ID: 22311537
    [No Abstract]   [Full Text] [Related]  

  • 71. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.
    Fernández-Mayoralas DM; Fernández-Jaén A; Muñoz-Jareño N; Calleja-Pérez B; Fernández-Perrone AL; Arribas SL
    Clin Neuropharmacol; 2012; 35(5):227-30. PubMed ID: 22935606
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment options for residual insomnia in schizophrenia.
    Baandrup L; Jennum P; Lublin H; Glenthoj B
    Acta Psychiatr Scand; 2013 Jan; 127(1):81-2. PubMed ID: 23106614
    [No Abstract]   [Full Text] [Related]  

  • 73. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
    Alphs L; Bossie CA; Fu DJ; Ma YW; Kern Sliwa J
    Expert Opin Pharmacother; 2014 May; 15(7):1029-42. PubMed ID: 24754314
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
    Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
    J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia.
    Younis IR; Laughren TP; Wang Y; Mathis M; Gobburu JV
    J Clin Psychopharmacol; 2013 Apr; 33(2):152-6. PubMed ID: 23422374
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful Long-Acting Paliperidone Treatment Following Reversible Risperidone-Induced Neutropenia.
    McGuire PR; Coplan BM; Puri S
    Prim Care Companion CNS Disord; 2020 Apr; 22(2):. PubMed ID: 32243107
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.